Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Performance of Spectral CT in Evaluating Treatment Response After Transarterial Chemoembolization for Hepatocellular Carcinoma: The SpecTRAIL Study

NCT07351669 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT07351669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07351669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Performance of Spectral CT in Evaluating Treatment Response After Transarterial Chemoembolization for Hepatocellular Carcinoma: The SpecTRAIL Study
Lead sponsor
Zhongda Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 20, 2026
Completion date
June 30, 2028
Enrollment
121 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ct, hcc - hepatocellular carcinoma, tace(transcatheter arterial chemoembolization)